Front‐line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real‐world setting : A multicenter retrospective study in China
Abstract Background The use of proteasome inhibitors (PIs), new immune modulators (IMiDs), and other new drugs, as well as high‐dose chemotherapy combined with autologous stem cell transplantation has considerably improved the survival of young patients with multiple myeloma (MM). However, the improvement in survival among elderly patients remains insufficient. Optimal treatment recommendation models for elderly patients with MM have not been developed especially there are quite few study in the real world. Methods We retrospectively analyzed the treatment patterns and outcomes of 328 Chinese patients (≥65 years) with MM in a real‐world setting. Patients were divided into three groups according to induction regimens. Results The median age of the cohort was 70 (65–86) years. The patients were divided into group 1 (PIs based regimens, n = 218), group 2 (IMiDs based regimens, n = 48) and group 3 (PIs + IMiDs, n = 62). Induction regimens in group 3 produced higher overall response rate than group 1 and 2 (85.42% vs. 71.08% vs. 66.67%, p = 0.016). The median follow‐up of the cohort was 30 (interquartile range [IQR] 18–36) months. For the entire cohort median progression‐free survival (PFS) was 26 (IQR 12.00–42.89) months and overall survival (OS) was 60 (IQR 40.00–67.20) months. The PFS were not significantly different among the three groups (28 months vs. 18 months vs. 26 months, p = 0.182). So were the OS (60 months vs. 59 months vs. not reached, p = 0.067). Multivariate analysis revealed that age >70 year, frailty status (Geriatric vulnerability score), induction efficacy < partial remission, and no maintenance treatment were independent poor prognostic factors for OS. Conclusion Front‐line induction regimens combining PIs and IMiDs developed more deep response than single PI or IMiD based regimens. Maintenance treatment can further improve the clinical outcome in elderly MM patients in real‐world setting..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancer Medicine - 12(2023), 3, Seite 3101-3111 |
| Beteiligte Personen: |
Bao, Li [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 Published by John Wiley & Sons Ltd. |
|---|
| Umfang: |
11 |
|---|
| doi: |
10.1002/cam4.5234 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015227987 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015227987 | ||
| 003 | DE-627 | ||
| 005 | 20231111133941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/cam4.5234 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_CAM4_2023_12_3.zip.xml |
| 035 | |a (DE-627)WLY015227987 | ||
| 035 | |a (WILEY)CAM45234 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Bao, Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Front‐line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real‐world setting |b A multicenter retrospective study in China |
| 264 | 1 | |c 2023 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Published by John Wiley & Sons Ltd. | ||
| 520 | |a Abstract Background The use of proteasome inhibitors (PIs), new immune modulators (IMiDs), and other new drugs, as well as high‐dose chemotherapy combined with autologous stem cell transplantation has considerably improved the survival of young patients with multiple myeloma (MM). However, the improvement in survival among elderly patients remains insufficient. Optimal treatment recommendation models for elderly patients with MM have not been developed especially there are quite few study in the real world. Methods We retrospectively analyzed the treatment patterns and outcomes of 328 Chinese patients (≥65 years) with MM in a real‐world setting. Patients were divided into three groups according to induction regimens. Results The median age of the cohort was 70 (65–86) years. The patients were divided into group 1 (PIs based regimens, n = 218), group 2 (IMiDs based regimens, n = 48) and group 3 (PIs + IMiDs, n = 62). Induction regimens in group 3 produced higher overall response rate than group 1 and 2 (85.42% vs. 71.08% vs. 66.67%, p = 0.016). The median follow‐up of the cohort was 30 (interquartile range [IQR] 18–36) months. For the entire cohort median progression‐free survival (PFS) was 26 (IQR 12.00–42.89) months and overall survival (OS) was 60 (IQR 40.00–67.20) months. The PFS were not significantly different among the three groups (28 months vs. 18 months vs. 26 months, p = 0.182). So were the OS (60 months vs. 59 months vs. not reached, p = 0.067). Multivariate analysis revealed that age >70 year, frailty status (Geriatric vulnerability score), induction efficacy < partial remission, and no maintenance treatment were independent poor prognostic factors for OS. Conclusion Front‐line induction regimens combining PIs and IMiDs developed more deep response than single PI or IMiD based regimens. Maintenance treatment can further improve the clinical outcome in elderly MM patients in real‐world setting. | ||
| 700 | 1 | |a Liu, Ai‐Jun |4 aut | |
| 700 | 1 | |a Chu, Bin |4 aut | |
| 700 | 1 | |a Wang, Qian |4 aut | |
| 700 | 1 | |a Dong, Yu‐Jun |4 aut | |
| 700 | 1 | |a Lu, Min‐Qiu |4 aut | |
| 700 | 1 | |a Shi, Lei |4 aut | |
| 700 | 1 | |a Gao, Shan |4 aut | |
| 700 | 1 | |a Wang, Yu‐Tong |4 aut | |
| 700 | 1 | |a Wang, Li‐Fang |4 aut | |
| 700 | 1 | |a Chen, Wen‐Ming |4 aut | |
| 700 | 1 | |a Zhuang, Jun‐Ling |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer Medicine |g 12(2023), 3, Seite 3101-3111 |w (DE-627)WLY003024768 |x 20457634 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:3 |g pages:3101-3111 |g extent:11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 3 |h 3101-3111 |g 11 | ||